
Results
34
Stocks where the price continues to rise after more than a year of consistent gains.
34 companies
argenx
Market Cap: €55.4b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€902.00
7D
23.5%
1Y
59.5%
Moderna
Market Cap: US$57.9b
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
MRNA
US$145.13
7D
129.2%
1Y
435.1%
BioNTech
Market Cap: US$27.9b
Engages in the development and commercialization of immunotherapies in Germany.
BNTX
US$116.57
7D
25.2%
1Y
5.1%
Genscript Biotech
Market Cap: HK$75.3b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$34.44
7D
38.4%
1Y
86.0%
Twist Bioscience
Market Cap: US$8.5b
Manufactures and sells synthetic DNA-based products.
TWST
US$145.59
7D
22.8%
1Y
409.2%
Amylyx Pharmaceuticals
Market Cap: US$4.4b
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
AMLX
US$38.66
7D
78.7%
1Y
315.7%
Walvax Biotechnology
Market Cap: CN¥25.7b
Engages in the research and development, manufacture, and distribution of vaccines in China and internationally.
300142
CN¥16.10
7D
21.2%
1Y
22.6%
SELLAS Life Sciences Group
Market Cap: US$2.7b
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SLS
US$15.46
7D
21.0%
1Y
709.4%
Maravai LifeSciences Holdings
Market Cap: US$2.2b
A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
MRVI
US$8.64
7D
51.6%
1Y
252.7%
Personalis
Market Cap: US$1.8b
Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
PSNL
US$18.38
7D
30.9%
1Y
280.5%
Basilea Pharmaceutica
Market Cap: CHF 813.6m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 64.60
7D
21.7%
1Y
36.1%
Jenkem Technology
Market Cap: CN¥6.5b
Engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol (PEG), and its derivatives in China and internationally.
688356
CN¥107.34
7D
30.6%
1Y
12.2%
Immix Biopharma
Market Cap: US$941.5m
A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
IMMX
US$13.66
7D
24.5%
1Y
523.7%
4D Molecular Therapeutics
Market Cap: US$889.4m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$15.83
7D
29.9%
1Y
123.3%
Hunan Hansen Pharmaceutical
Market Cap: CN¥5.1b
Engages in the production and sale of traditional Chinese preparations in China and internationally.
002412
CN¥10.19
7D
39.2%
1Y
49.0%
Nuvectis Pharma
Market Cap: US$760.8m
A clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
NVCT
US$23.56
7D
24.3%
1Y
242.9%
Shanghai Shenqi Pharmaceutical Investment Management
Market Cap: CN¥4.5b
Operates as a pharmaceutical manufacturing holding investment company in China.
600613
CN¥9.00
7D
40.4%
1Y
28.0%
OmniAb
Market Cap: US$625.2m
A biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
OABI
US$4.33
7D
28.1%
1Y
134.1%
Contineum Therapeutics
Market Cap: US$602.7m
A clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
CTNM
US$17.19
7D
21.1%
1Y
72.9%
Xinjiang Tianshan Animal Husbandry Bio-engineering
Market Cap: CN¥3.1b
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.
300313
CN¥12.80
7D
43.2%
1Y
46.6%
ProQR Therapeutics
Market Cap: US$320.3m
A clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
PRQR
US$2.34
7D
21.9%
1Y
3.5%
AVITA Medical
Market Cap: US$312.1m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
RCEL
US$10.06
7D
28.2%
1Y
106.1%
Nykode Therapeutics
Market Cap: NOK 1.5b
A clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases.
NYKD
NOK 4.51
7D
33.2%
1Y
158.2%
Cypherpunk Technologies
Market Cap: US$128.2m
A privacy technology company, implements a digital asset strategy anchored by Zcash in the United States.
CYPH
US$1.42
7D
120.5%
1Y
376.8%
Psomagen
Market Cap: ₩78.0b
Engages in the provision omics solutions and contract laboratory services.
A950200
₩4,055.00
7D
39.3%
1Y
2.9%
Bilcare
Market Cap: ₹2.3b
Provides pharmaceutical packaging research solutions in India and internationally.
526853
₹94.08
7D
22.0%
1Y
40.5%
Pharmala Biotech Holdings
Market Cap: CA$25.1m
A biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community.
MDMA
CA$0.27
7D
43.2%
1Y
103.8%
Aton
Market Cap: €12.8m
Operates as a bioscience company in France.
ALTAO
€0.015
7D
20.6%
1Y
85.4%
Malaysian Genomics Resource Centre Berhad
Market Cap: RM 57.4m
Provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia.
MGRC
RM 0.38
7D
22.6%
1Y
94.9%
BioVie
Market Cap: US$14.0m
A clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
BIVI
US$1.95
7D
39.3%
1Y
21.9%
Dannex Ayrton Starwin
Market Cap: GH₵98.3m
Engages in the manufacturing, importing, and sale of pharmaceutical products in Ghana.
DASPHARMA
GH₵1.27
7D
56.8%
1Y
234.2%
International Stem Cell
Market Cap: US$3.6m
A clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.
ISCO
US$0.50
7D
42.3%
1Y
241.8%
Emmaus Life Sciences
Market Cap: US$1.8m
A commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
EMMA
US$0.032
7D
179.1%
1Y
156.8%
ObsEva
Market Cap: US$11.7k
A biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health.
OBSE.F
US$0.0001
7D
9,900.0%
1Y
0%